Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders.
Financial Results:
Suven Life Sciences Ltd reported Revenues for Q1FY24 of ₹4.00 Crores same from ₹4.00 Crore year on year.
Total Expenses for Q1FY24 of ₹34.00 Crores up from ₹27.00 Crores year on year, a rise of 25.93%.
Consolidated Net Profit of -₹24.00 Crores from -₹16.00 Crores in the same quarter of the previous year.
The Earnings per Share is -₹1.10, from -₹0.75 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.